Combination treatment for resistant hypertension

Combining atrial natriuretic peptide with a diuretic like furosemide addresses the challenge of resistant hypertension by lowering blood pressure and reducing aldosterone stimulation, offering an effective treatment.

JP2024156691AInactive Publication Date: 2024-11-06MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Patent Information

Application Number
JP2024111406
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-09
Filing Date
2024-07-11
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for resistant hypertension are ineffective, as blood pressure remains elevated despite the use of multiple antihypertensive drug classes, with no approved drugs or devices in the United States.

Method used

The combination therapy of atrial natriuretic peptide (MANP) and a diuretic, such as furosemide, is administered to patients with resistant hypertension to lower blood pressure and suppress aldosterone stimulation.

Benefits of technology

This combination effectively reduces blood pressure and minimizes adverse effects, providing a therapeutic approach for resistant hypertension.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156691000004
    Figure 2024156691000004
  • Figure 2024156691000005
    Figure 2024156691000005
  • Figure 2024156691000006
    Figure 2024156691000006
Patent Text Reader

Abstract

To provide pharmaceuticals for treating patients with resistant hypertension (RH).SOLUTION: Materials, methods and pharmaceutical compositions for treating hypertension (including resistant hypertension) with a combination of an M-atrial natriuretic peptide (MANP) and a diuretic agent (e.g., furosemide) are provided herein.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority from U.S. Provisional Application No. 62 / 758,009, filed November 9, 2018. The disclosure of the prior application is hereby incorporated by reference into the disclosure of this application.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with government support under HL136340 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] Technical Field This specification relates to materials and methods for treating hypertension, and more particularly to a method for treating a mammal with resistant hypertension using the combination of M atrial natriuretic peptide (MANP) and a diuretic (e.g., furosemide). [Background technology]

[0004] background Hypertension (HT), also known as high blood pressure, is a long-term medical condition characterized by persistently elevated blood pressure in the arteries. Hypertension gradually becomes resistant to treatment with antihypertensive drugs. Patients with resistant hypertension (RH) have elevated blood pressure despite combination treatment with (1) a diuretic and typically three antihypertensive drugs from different classes, including (2) an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), and (3) a calcium channel blocker (CCB). Patients whose blood pressure is controlled with four or more drugs are also considered to have RH. Currently, there are no drugs or devices approved in the United States for the treatment of RH. Summary of the Invention

[0005] overview The present disclosure is based, at least in part, on the discovery that the combination of MANP and a diuretic has a strong blood pressure (BP) lowering effect while suppressing furosemide (Fs)-induced aldosterone stimulation. This discovery demonstrated that RH can be effectively treated by the combination of MANP and a diuretic such as furosemide (Fs).

[0006] In a first aspect, the present specification features a method of treating a mammal, which can include administering to the mammal a MANP and a diuretic. The mammal can be one identified as having hypertension (e.g., RH). The MANP can have the amino acid sequence set forth in SEQ ID NO: 3, or any one of SEQ ID NOs: 5-14. The diuretic can be furosemide. The mammal can be a human. The MANP can be administered intravenously (e.g., at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min). The MANP can be administered subcutaneously (e.g., at a dose of about 0.1 ng / kg to about 10 mg / kg). The MANP can be administered intravenously and then subcutaneously. For example, the MANP can be administered intravenously at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min, and then subcutaneously at a dose of about 0.1 ng / kg to about 100 mg / kg. The diuretic can be administered orally, intravenously, or subcutaneously. The MANP and the diuretic can be administered simultaneously in the same composition. The MANP and the diuretic can be administered subcutaneously. The method can comprise administering the MANP and the diuretic to the mammal. The MANP and the diuretic can be administered as a composition in which the MANP and the diuretic are all active ingredients.

[0007] In another aspect, the description features a method for enhancing one or more beneficial effects of a diuretic and reducing one or more adverse effects of a diuretic in a mammal, the method comprising administering a diuretic and a MANP to the mammal. The mammal can be identified as having hypertension (e.g., RH). The MANP can have an amino acid sequence set forth in SEQ ID NO: 3, or an amino acid sequence set forth in any one of SEQ ID NOs: 5-14. The diuretic can be furosemide. The mammal can be a human. The MANP and the diuretic can be administered intravenously (e.g., where the MANP is administered at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min). The MANP and the diuretic can be administered subcutaneously (e.g., where the MANP is administered at a dose of about 1 μg / kg to about 10 μg / kg). The MANP and the diuretic can be administered intravenously and then subcutaneously. MANP can be administered intravenously at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min, followed by subcutaneous administration at a dose of about 1 μg / kg to about 10 μg / kg. The one or more beneficial effects can include lowering blood pressure in the mammal, and the one or more adverse effects can include activation of aldosterone. The method can comprise administering a composition having a diuretic and a MANP as all active ingredients. The MANP and the diuretic can be administered as a composition having a MANP and a diuretic as all active ingredients.

[0008] Unless otherwise specified, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. The present invention can be carried out using methods and materials similar or equivalent to those described herein, and suitable methods and materials are described below. All publications, patent applications, patents, and other references described herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, shall control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0009] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 shows the sequence and general structure of atrial natriuretic peptide (ANP; SEQ ID NO:1) and the sequence and general structure of MANP (SEQ ID NO:3). [Figure 2A] 2A-2C are graphs plotting mean arterial pressure (MAP) in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 2A); MAP in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 2B); and MAP in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 2C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, # p<0.05 vs. Fs10. [Figure 2B]2A-2C are graphs plotting mean arterial pressure (MAP) in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 2A); MAP in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 2B); and MAP in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 2C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, # p<0.05 vs. Fs10. [Figure 2C] 2A-2C are graphs plotting mean arterial pressure (MAP) in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 2A); MAP in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 2B); and MAP in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 2C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, # p<0.05 vs. Fs10. [Figure 3A]3A-3C are graphs plotting plasma cGMP levels in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 3A); plasma cGMP levels in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 3B); and plasma cGMP levels in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 3C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, @ p<0.05 vs. MANP100. [Figure 3B] 3A-3C are graphs plotting plasma cGMP levels in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 3A); plasma cGMP levels in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 3B); and plasma cGMP levels in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 3C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, @ p<0.05 vs. MANP100. [Figure 3C]3A-3C are graphs plotting plasma cGMP levels in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, or 600 pmol / kg / min MANP (FIG. 3A); plasma cGMP levels in rats administered vehicle, 1 mg / kg Fs, 5 mg / kg Fs, or 10 mg / kg Fs (FIG. 3B); and plasma cGMP levels in rats administered vehicle, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs (FIG. 3C) over a 60 minute period. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. *p<0.05 vs. vehicle, @ p<0.05 vs. MANP100. [Figure 4] FIG. 4 is a graph plotting plasma aldosterone concentrations in rats administered vehicle, 100 pmol / kg / min MANP, 300 pmol / kg / min MANP, 600 pmol / kg / min MANP, 1 mg / kg Fs, 5 mg / kg Fs, 10 mg / kg Fs, 300 pmol / kg / min MANP + 5 mg / kg Fs, 600 pmol / kg / min MANP + 5 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs for 60 minutes. MANP had the amino acid sequence set forth in SEQ ID NO:3. Data are presented as mean ± SD. $p<0.05 vs. Fs5, #p<0.05 vs. Fs10. [Diagram 5] 5 is a graph plotting the change in MAP versus the change in cGMP levels after administration of vehicle, 100, 300, or 600 pmol / kg / min MANP, 1, 5, or 10 mg / kg Fs, or 300 pmol / kg / min MANP + 5 mg / kg Fs, 300 pmol / kg / min MANP + 10 mg / kg Fs, or 600 pmol / kg / min MANP + 10 mg / kg Fs to rats for 60 minutes. MANP had the amino acid sequence set forth in SEQ ID NO:3. [Figure 6]Figures 6A-6C are graphs plotting the levels of cGMP produced in human embryonic kidney 293 (HEK293) cells overexpressing particulate guanylate cyclase A (pGC-A) receptors (Figure 6A), primary human aortic endothelial cells (HAEC) (Figure 6B), and primary human aortic smooth muscle cells (HASMC) (Figure 6C) stimulated with MANP (SEQ ID NO: 3). Values ​​shown are mean ± SEM. * p< 0.05 vs. control. [Figure 7] 7A-7C are graphs plotting BP in rats at baseline (BL), 15 min lead-in, and 15, 30, 45, and 60 min following MANP or vehicle (control) injection (FIG. 7A), Fs or vehicle (control) bolus injection (FIG. 7B), and combined MANP and Fs bolus injections or combined vehicle and vehicle bolus injections (FIG. 7C). Values ​​shown are mean±SEM. # p<0.05 MANP300 vs. solvent; * p<0.05 MANP600 vs. solvent; § p<0.05 Fs1 vs. solvent; @ p<0.05 Fs5 vs. solvent; & p<0.05 Fs10 vs. solvent; £ p<0.05 MANP300+Fs5 vs. solvent; (R) p<0.05 MANP300+Fs10 vs. solvent; (C) p<0.05 MANP600+Fs10 vs. solvent. MANP had the amino acid sequence set forth in SEQ ID NO:3. [Figure 8] 8 is a graph plotting BP in rats after 60 minutes of vehicle injection (control), MANP injection, Fs bolus injection, or combined MANP and Fs bolus injection. Values ​​plotted are mean ± SEM. * p<0.05 vs. vehicle; \ p<0.05 vs. MANP100; (R) p<0.05 MANP300 vs. MANP300+Fs10; # p<0.05 vs. MANP600; § p<0.05 vs. Fs1; @ p<0.05 vs. Fs5; & p<0.05 vs. Fs10. MANP had the amino acid sequence set forth in SEQ ID NO:3. [Figure 9]9A-9C are graphs plotting plasma cGMP in rats at BL, 30 and 60 min after injection of MANP or vehicle (control) (FIG. 9A), bolus injection of Fs or vehicle (control) (FIG. 9B), and combined MANP and Fs bolus injections or vehicle and vehicle bolus injections (control) (FIG. 9C). Values ​​plotted are mean±SEM. *p<0.05 vs. vehicle. MANP was determined to have the amino acid sequence set forth in SEQ ID NO:3. [Figure 10] Figure 10 is a graph plotting urinary cGMP excretion in rats 60 minutes after administration of MANP (SEQ ID NO: 3), Fs, the combination of MANP+Fs, or vehicle. Values ​​plotted are mean ± SEM. * p<0.05 vs. vehicle (control). [Figure 11] Figure 11 is a graph plotting aldosterone levels in rats 60 minutes after administration of MANP (SEQ ID NO: 3), Fs, the combination of MANP+Fs, or vehicle. Values ​​shown are mean ± SEM. * p<0.05 vs. vehicle (control); @ p<0.05 vs. Fs5; & p<0.05 vs. Fs10. [Figure 12] 12 is a graph showing the positive correlation between plasma ANP and plasma cGMP in rats after administration of MANP (SEQ ID NO: 3), Fs, the combination of MANP+Fs, or vehicle. Pearson's correlation coefficient (r)=0.7479, p<0.01. [Figure 13] 13 is a graph plotting the negative correlation between plasma cGMP and mean arterial blood pressure in rats following administration of MANP (SEQ ID NO: 3), Fs, the combination of MANP+Fs, or vehicle. Pearson's correlation coefficient (r)=-0.6510, p<0.01. [Figure 14]Figures 14A-14C are graphs plotting GFR (Figure 14A), urinary sodium excretion (Figure 14B) and urine flow (Figure 14C) 60 minutes after administration of MANP (SEQ ID NO: 3), Fs, the combination of MANP+Fs or vehicle. Values ​​shown are mean ± SEM. * p<0.05 vs. vehicle (control); \ p<0.05 vs. MANP100; (R) p<0.05 vs. MANP300; @ p<0.05 vs. MANP600; # p<0.05 vs. Fs1; & p<0.05 vs. MANP300+Fs5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Detailed Description The present disclosure provides materials and methods for treating hypertension, including RH, with a combination of MANP and a diuretic (e.g., Fs). For example, the present disclosure provides a method comprising administering MANP and a diuretic to a mammal (e.g., human, non-human primate, dog, cat, rat, mouse, cow, horse, sheep, or pig) such that the BP of the mammal is reduced after administration. In some cases, aldosterone is not elevated in the mammal after administration. In some cases, the mammal can be identified as having hypertension (e.g., RT).

[0012] Diuretics, commonly known as "water pills," are medications that help the kidneys flush excess fluid and salt from the body, thereby lowering fluid levels in the blood vessels and lowering blood pressure. Diuretics are often the first type of medication prescribed to patients with high blood pressure. Diuretics that can be used to treat patients with high blood pressure include thiazide diuretics [e.g., chlorthalidone (Hygroton), chlorothiazide (Diuril), hydrochlorothiazide (Esidrix, Hydrodiuril, or Microzide), indapamide (Lozol), and metolazone (Mykrox, Zaroxolyn)], as well as others, including, but not limited to, amiloride (Midamol), bumetanide (Bumex), furosemide (Lasix), spironolactone (Aldactone), and triamterene (Direnium). Furosemide (abbreviated herein as "Fs") can enhance the effectiveness of other antihypertensive drugs, but Fs also activates the renin-angiotensin-aldosterone system.

[0013] A natriuretic polypeptide is a polypeptide that can cause natriuresis, which increases the excretion of sodium in urine. Natriuretic polypeptides can be produced by the brain, heart, kidney, and / or vascular tissue. The human natriuretic polypeptide family includes the cardiac hormones atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and urodilatin (URO). Natriuretic polypeptides function through two well-characterized guanylate cyclase receptors (NPR-A for ANP, BNP, and URO, and NPR-B for CNP) and the second messenger cyclic 3´,5´-guanosine monophosphate (cGMP) (Kuhn (2003) Circ. Res. 93:700-709; Tawaragi et al. (1991) Biochem. Biophys. Res.Commun. 175:645-651; and Komatsu et al. (1991) Endocrinol. 129:1104-1106). Natriuretic polypeptides may be effective, for example, in increasing plasma cGMP levels, increasing urinary cGMP excretion, increasing net renal cGMP production, increasing urine flow, increasing urinary sodium excretion, increasing urinary potassium excretion, increasing hematocrit, increasing plasma BNP immunoreactivity, increasing renal blood flow, increasing plasma ANP immunoreactivity, decreasing renal vascular resistance, decreasing proximal and distal fractional reabsorption of sodium, decreasing mean arterial pressure, decreasing pulmonary capillary wedge pressure, decreasing right atrial pressure, decreasing pulmonary artery pressure, decreasing plasma renin activity, decreasing plasma angiotensin II concentration, decreasing plasma aldosterone concentration, decreasing renal perfusion pressure, and / or decreasing systemic vascular resistance.

[0014] MANP is a pGC-A / cGMP activator that can significantly reduce blood pressure and vascular resistance. The methods described herein can include, in part, treating a mammal with MANP. As shown in FIG. 1, MANP is an ANP-based peptide having an amino acid sequence that includes the 28 amino acid mature human ANP sequence (SLRRSSCFGGRMDRIGAQSGLGCNSFRY; SEQ ID NO: 1) plus a 12 amino acid carboxy terminus (RITAREDKQGWA; SEQ ID NO: 2). The full length sequence of MANP is SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQGWA (SEQ ID NO: 3). A representative nucleic acid sequence encoding MANP is 5′-agcctgcggagatccagctgcttcgggggcaggatggacaggattggagcccagagcggactgggctgtaacagcttccggtaccggataacagccagggaggacaagcagggctgggcctag-3′ (SEQ ID NO: 4).

[0015] A "MANP" as used herein can have the amino acid sequence set forth in SEQ ID NO:3 or can be a variant of the sequence set forth in SEQ ID NO:3. Thus, in some cases, a MANP used in the methods described herein can comprise the entire amino acid sequence set forth in SEQ ID NO:3. In some cases, a MANP can comprise the amino acid sequence set forth in SEQ ID NO:3, provided that the amino acid sequence comprises one, or between one and ten (e.g., ten, between one and nine, between two and nine, between one and eight, between two and eight, between one and seven, between one and six, between one and five, between one and four, between one and three, two, or one) amino acid additions, deletions, and / or substitutions. For example, a MANP can comprise the amino acid sequence set forth in SEQ ID NO:3 with one, two, three, four, five, six, seven, eight, nine, or ten single amino acid residue additions, deletions, or substitutions. In some cases, a MANP can have one or more additions, deletions, and / or substitutions in the C-terminal portion of SEQ ID NO: 3 (e.g., the last 12 amino acids of SEQ ID NO: 3). Examples of such polypeptides include, but are not limited to, a polypeptide having an amino acid sequence set forth in SEQ ID NO: 3, in which a threonine is deleted (SLRRSSCFGGRMDRIGAQSGLGCNSFRYRIAREDKQGWA; SEQ ID NO: 5), a tryptophan is replaced with a tyrosine (SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQGYA; SEQ ID NO: 6), a serine is added between the lysine and glutamine (SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKSQGWA; SEQ ID NO: 7), or any combination thereof. In another example, a MANP can lack the last three residues of SEQ ID NO:3 (ie, the glycine, tryptophan, and alanine residues of SEQ ID NO:3), as set forth in SEQ ID NO:8 (SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQ).In some examples, MANP can have one or more additions, deletions, and / or substitutions in the N-terminal portion of SEQ ID NO:3 (e.g., the first six amino acids of SEQ ID NO:3). Examples of such polypeptides include the polypeptide having the amino acid sequence set forth in SEQ ID NO:3, in which four amino acids from urodilatin have been added to the N-terminus (TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQGWA; SEQ ID NO:9), the polypeptide in which the arginine residues at positions 3 and 4 have been replaced with lysine residues (SLKKSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQGWA; SEQ ID NO:10), the polypeptide in which the serine at position 6 is replaced with that of the D isoform (SLRRSSCFGGRMDRIGQSGLGCNSFRYRITAREDKQGWA; SEQ ID NO:11), the polypeptide in which the serine at position 4 is replaced with that of the D isoform and the serine at position 5 is deleted (SLRRSSCFGGRMDRIGQSGLGCNSFRYRITAREDKQGWA; SEQ ID NO:12), the polypeptide in which the serine at position 5 is deleted with that of the D isoform (SLRRSSCFGGRMDRIGQSGLGCNSFRYRITAREDKQGWA; SEQ ID NO:13), the polypeptide in which the serine at position 4 is replaced with that of the D isoform and the serine at position 5 is deleted (SLRRSSCFGGRMDRIGAQSGL GCNSFRYRITAREDKQGWA; SEQ ID NO: 12), the polypeptide in which the serine residues at positions 1, 5, and 6 are replaced with threonine residues (TLRRTTCFGGRMDRIGAQSGLGCNSFR YRITAREDKQGWA; SEQ ID NO: 13), the polypeptide in which the leucine at position 2 is replaced with tryptophan (SWRRSSCFGGRMDR IGAQSGLGCNSFRY RITAREDKQGWA; SEQ ID NO: 14), or any combination thereof.

[0016] Any amino acid residue set forth in SEQ ID NO: 3 can be deleted, but any amino acid residue (e.g., any of the 20 common amino acid residues or other types of amino acids such as ornithine or citrulline) can be added to the sequence set forth in SEQ ID NO: 3. In some cases, MANPs can include one or more chemical structures such as ε-aminohexanoic acid; hydroxylated amino acids, such as 3-hydroxyproline, 4-hydroxyproline, (5R)-5-hydroxy-L-lysine, allohydroxylysine, and 5-hydroxy-L-norvaline; and / or glycosylated amino acids, such as amino acids that include a monosaccharide (e.g., D-glucose, D-galactose, D-mannose, D-glucosamine, D-galactosamine) or a combination of monosaccharides.

[0017] MANPs having one or more amino acid additions, deletions, or substitutions relative to the representative MANP sequence set forth in SEQ ID NO:3 (also referred to herein as "variant" MANPs) can be made by any suitable method. In some cases, amino acid substitutions can be made by selecting substitutions that do not significantly alter the effect on maintaining (a) the structure of the peptide backbone in the region of substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. For example, naturally occurring residues can be grouped based on the properties of their side chains: (1) hydrophobic amino acids (norleucine, methionine, alanine, valine, leucine, and isoleucine); (2) neutral hydrophilic amino acids (cysteine, serine, and threonine); (3) acidic amino acids (aspartic acid and glutamic acid); (4) basic amino acids (asparagine, glutamine, histidine, lysine, and arginine); (5) amino acids that affect chain directionality (glycine and proline); and (6) aromatic amino acids (tryptophan, tyrosine, and phenylalanine). Substitutions made within these groups can be considered conservative substitutions.Non-limiting examples of useful conservative substitutions can include, but are not limited to, valine for alanine, lysine for arginine, glutamine for asparagine, glutamic acid for aspartic acid, serine for cysteine, asparagine for glutamine, aspartic acid for glutamic acid, proline for glycine, arginine for histidine, leucine for isoleucine, isoleucine for leucine, arginine for lysine, leucine for methionine, leucine for phenylalanine, glycine for proline, threonine for serine, serine for threonine, tyrosine for tryptophan, phenylalanine for tyrosine, and / or leucine for valine.

[0018] Further examples of conservative substitutions that can be made at any position within a MANP that are useful in the methods described herein are listed in Table 1.

[0019] In some embodiments, MANP can include one or more non-conservative substitutions. Non-conservative substitutions typically require replacing a member of one of the above classes with a member of another class. Such production may be desirable to provide a large amount of the compound or to provide other embodiments of the compound. Whether an amino acid change results in a functional polypeptide can be easily determined, for example, by assaying the specific activity of the polypeptide variant using the methods described herein.

[0020] In some embodiments, the MANP can have a length of, for example, 35-45 amino acid residues (e.g., 35-40, 40-45, 35-37, 36-38, 37-39, 38-40, 39-41, 40-42, 41-43, 42-44, or 43-45 amino acid residues). In some embodiments, the natriuretic polypeptide can include an amino acid sequence as set forth in SEQ ID NO: 3, but with a certain number of amino acid substitutions. For example, the natriuretic polypeptide can have the amino acid sequence of SEQ ID NO: 3, but with one, two, three, four, or five amino acid substitutions. Examples of such amino acid sequences include, but are not limited to, MANPs with D-amino acid substitutions in place of one or more L-amino acids in the N-terminal region of the polypeptide (e.g., a MANP with a D-serine residue at position 6 as set forth in SEQ ID NO: 11, or a D-arginine at position 4 as set forth in SEQ ID NO: 12).

[0021] [Table 1]

[0022] In some embodiments, a MANP can include an amino acid sequence that has at least 90% (e.g., at least 90%, at least 92.5%, at least 95%, at least 97.5%, or 100%) sequence identity with the reference sequence set forth in SEQ ID NO:3. The percentage of sequence identity is calculated by determining the number of matching positions in the aligned amino acid sequences, dividing the number of matching positions by the total number of aligned amino acids, and multiplying by 100. A matching position refers to a position where an identical amino acid exists at the same position in the aligned amino acid sequences. The percentage of sequence identity can also be determined for any nucleic acid sequence.

[0023] The percent sequence identity between a particular nucleic acid or amino acid sequence and a sequence referenced by a particular sequence identification number is determined as follows: First, the nucleic acid or amino acid sequence is compared to the sequence set forth in a particular sequence identification number using the BLAST 2 Sequences (Bl2seq) program from the standalone version of BLASTZ, including BLASTN version 2.0.14 and BLASTP version 2.0.14. This standalone version of BLASTZ is available online at fr.com / blast or ncbi.nlm.nih.gov. Instructions explaining how to use the Bl2seq program are provided in the readme file that accompanies BLASTZ. Bl2seq performs a comparison of two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences and BLASTP is used to compare amino acid sequences. When comparing two nucleic acid sequences, the options are set as follows: -i to the file containing the first nucleic acid sequence to be compared (e.g., C:\seq1.txt); -j to the file containing the second nucleic acid sequence to be compared (e.g., C:\seq2.txt); -p to blastn; -o to any desired file name (e.g., C:\output.txt); -q to -1; -r to 2, and all other options are left at their default settings. For example, the following command can be used to create an output file containing a comparison between two sequences; C:\Bl2seq -ic:\seq1.txt -jc:\seq2.txt -p blastn -oc:\output.txt -q -1 -r 2. If comparing two amino acid sequences, set the Bl2seq options as follows: -i to the file containing the first amino acid sequence to be compared (e.g., C:\seq1.txt); -j to the file containing the second amino acid sequence to be compared (e.g., C:\seq2.txt); -p to blastp; -o to any desired file name (e.g., C:\output.txt), and leave all other options at their default settings.For example, the following command can be used to create an output file containing a comparison of two amino acid sequences: C:\Bl2seq -ic:\seq1.txt -jc:\seq2.txt -p blastp -oc:\output.txt. If the two compared sequences are homologous, the specified output file will present the regions of homology as aligned sequences. If the two compared sequences are not homologous, the specified output file will not display aligned sequences.

[0024] Once alignment is complete, the number of matches is determined by counting the number of positions where identical nucleotides or amino acid residues appear in both sequences. The percent sequence identity is determined by dividing the number of matches by the length of the sequence described in a particular sequence (e.g., SEQ ID NO:3) or by a concatenated length (e.g., 20 consecutive nucleotides or amino acid residues from the sequence described in a particular sequence), and then multiplying the resulting value by 100. For example, an amino acid sequence that has 37 matches when aligned with the sequence described in SEQ ID NO:3 is 92.5 percent identical to the sequence described in SEQ ID NO:3 (i.e., 37÷40×100=92.5). It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, and 75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. Also note that length values ​​are always integers.

[0025] Isolated MANPs can be produced by any suitable method, including solid phase synthesis, and can be made using manual or automated techniques (e.g., using the Peptide Synthesizer from Applied BioSystems (Foster City, Calif.), or the automated peptide synthesizer from Biosearch Inc. (San Rafael, Calif.). Disulfide bonds between cysteine ​​residues can be introduced by mild oxidation of linear polypeptides with KCN, for example, as taught in U.S. Pat. No. 4,757,048. Natriuretic polypeptides can also be made recombinantly or purchased commercially.

[0026] The MANPs described herein are typically cyclic due to disulfide bonds between cysteine ​​residues (see FIG. 1). In some embodiments, the sulfhydryl group on the cysteine ​​residue can be replaced with another group (e.g., -CH2CH2-). To replace the sulfhydryl group with a -CH2- group, for example, the cysteine ​​residue can be replaced with α-aminobutyric acid. Such cyclic analog polypeptides can be made, for example, according to the method of Lebl and Hruby ((1984) Tetrahedron Lett. 25:2067-2068) or using the procedures disclosed in U.S. Pat. No. 4,161,521.

[0027] Additionally, ester bridges can be formed by reacting the OH of serine or threonine with the carboxyl group of aspartic acid or glutamic acid, resulting in a bridge with the structure -CH2CO2CH2-. Similarly, amides can be obtained by reacting the side chain of lysine with aspartic acid or glutamic acid, resulting in a bridge with the structure -CH2C(O)NH(CH)4-. Methods for synthesizing these bridges are known in the art (see, for example, Schiller et al. (1985) Biochem. Biophys. Res. Comm. 127:558, and Schiller et al. (1985) Int. J. Peptide Protein Res. 25:171). For example, one method for preparing esters of the polypeptides of the invention is to cleave the completed polypeptide from the resin in the presence of the desired alcohol under basic or acidic conditions, depending on the resin, when using the Merrifield synthesis. The C-terminus of the polypeptide, once cleaved from the resin, can then be directly esterified without isolating the free acid. Amides of polypeptides can also be prepared using techniques (e.g., techniques known in the art) that convert carboxylic acid groups or precursors to amides. One method for forming amides at the C-terminal carboxyl group includes cleaving the polypeptide from the solid support with an appropriate amine, or cleaving in the presence of an alcohol to give an ester followed by aminolysis with the desired amine. Other bridge-forming amino acid residues and reactions are described, for example, in U.S. Pat. No. 4,935,492. Preparation of peptide analogs containing non-peptide bonds linking amino acid residues is also known in the art.For example, Spatola et al. (1986) Life Sci. 38:1243; Spatola (1983) Vega Data 1(3); Morley (1980) Trends Pharm. Sci. 463-468; Hudson et al. (1979) Int. J. Pept. Prot. Res. 14:177; Spatola, in Chemistry and Biochemistry of Amino Acid Peptides and Proteins, B. Weinstein, ed., Marcel Dekker, New York, p. 267 (1983); Hann (1982) J. Chem. Soc. Perkin Trans. 1:307; Almquist et al. (1980) J. Med. Chem. 23:1392; Jennings-White et al. (1982) Tetrahedron Lett. 23:2533; European See Patent Application EP 45665; Holladay et al. (1983) Tetrahedron Lett. 24:4401; and Hruby (1982) Life Sci. 31:189.

[0028] N-acyl derivatives of amino groups of polypeptides can be prepared by utilizing N-acyl protected amino acids for the final condensation or by acylating protected or unprotected peptides. O-acyl derivatives can be prepared, for example, by acylating free hydroxypeptides or peptide resins. Both acylations can be carried out with standard acylating reagents such as acyl halides, anhydrides, acylimidazoles, etc. If desired, both N- and O-acylations can be carried out together.

[0029] In some cases, the MANP can be pegylated, acetylated, or both. In some cases, the polypeptide can be covalently attached to an oligomer, such as a short amphipathic oligomer, that allows administration or improves the pharmacokinetic or pharmacodynamic properties of the attached polypeptide. The oligomer can include water-soluble polyethylene glycol (PEG) and / or a lipophilic alkyl (short, medium, or long chain fatty acid polymers, such as, but not limited to, palmitic acid, myristic acid, lauric acid, capric acid, or steric acid). The fatty acid molecule can be attached to the free amino terminus or to any lysine side chain (ε-amino group), although the lysine residue for this attachment can be located at either the C-terminus or the N-terminus of the peptide. Conjugation with PEG or other suitable polymers, or fusion with albumin or other suitable polypeptides, can result in modified natriuretic peptides with extended half-life compared to unmodified natriuretic polypeptides. Without being bound to a particular mechanism, it is believed that the increased serum half-life is due to reduced proteolysis, immune recognition, or cellular scavenging of the modified natriuretic polypeptide. Methods for modifying polypeptides by conjugation with PEG (also referred to as "PEGylation") or conjugation with other polymers are known in the art, including those described in U.S. Patent No. 6,884,780; PCT Publication No. WO 2004 / 047871; Cataliotti et al. ((2007) Trends Cardiovasc. Med. 17:10-14; Veronese and Mero (2008) BioDrugs 22:315-329; Miller et al. (2006) Bioconjugate Chem. 17:267-274; and Veronese and Pasut (2005) Drug Discov. Today 10:1451-1458, all of which are incorporated herein by reference in their entirety.Methods for modifying polypeptides by fusion with albumin are also known in the art and include those described in U.S. Patent Publication No. 20040086976, and Wang et al. (2004) Pharm. Res. 21:2105-2111, both of which are incorporated by reference herein in their entireties.

[0030] In some cases, the MANP can be fused to the Fc domain of an immunoglobulin molecule (e.g., an IgG1 molecule) to allow active transport of the fusion polypeptide across an epithelial cell barrier via the Fc receptor. In some cases, the polypeptide can be a cyclic polypeptide. A cyclic polypeptide can be obtained by linking cysteine ​​residues, but it is also envisioned to replace the sulfhydryl group on the cysteine ​​residue with another group, such as -CH2-CH2-. For example, the cysteine ​​residue can be replaced with the analogous α-aminobutyric acid to replace the sulfhydryl group with a -CH2- group. These cyclic analog peptides can be made, for example, according to the method of Lebl and Hruby (Tetrahedron Lett., 25:2067-2068, 1984) or using the procedure disclosed in U.S. Pat. No. 4,161,521.

[0031] Salts of carboxyl groups of MANPs can be prepared by contacting the polypeptide with one or more equivalents of a desired base, such as a metal hydroxide base (e.g., sodium hydroxide), a metal carbonate or bicarbonate base (e.g., sodium carbonate or bicarbonate), or an amine base (e.g., triethylamine, triethanolamine, etc.) Acid addition salts of the polypeptide can be prepared by contacting the polypeptide with one or more equivalents of an inorganic or organic acid (e.g., hydrochloric acid).

[0032] As used herein, the term "polypeptide" refers to a compound consisting of two or more subunit amino acids, with or without post-translational modification (e.g., phosphorylation or glycosylation). The subunits may be linked by peptide bonds or other bonds, such as ester or ether bonds. The term "amino acid" refers to either natural amino acids, including D / L optical isomers, and / or unnatural or synthetic amino acids.

[0033] The term "isolated" as used herein with respect to a polypeptide means that the polypeptide is (1) not associated with naturally occurring proteins, (2) free of other proteins from the same source (e.g., free of human proteins), (3) expressed by a cell of a different species, or (4) not naturally occurring. An isolated polypeptide may be, for example, encoded by DNA or RNA, including synthetic DNA or RNA, or encoded by any combination thereof.

[0034] The term "substantially pure" as used herein with respect to a polypeptide means that the polypeptide is substantially free of other polypeptides, lipids, carbohydrates, and nucleic acids with which it is naturally associated. A substantially pure polypeptide can be any polypeptide that is removed from its natural environment and has a purity of at least 60%. A substantially pure polypeptide can be at least about 65, 70, 75, 80, 85, 90, 95, or 99 percent pure, or about 65-75, 75-80, 80-85, 85-90, 90-95, or 95-99 percent pure. Typically, a substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. In some embodiments, a substantially pure polypeptide can be a chemically synthesized polypeptide.

[0035] Any method can be used to obtain substantially pure polypeptides. For example, common polypeptide purification techniques such as affinity chromatography and HPLC, as well as polypeptide synthesis techniques can be used. Furthermore, any material can be used as a source to obtain substantially pure polypeptides. For example, wild-type and transgenic animal tissues can be used as source materials. In addition, tissue culture cells engineered to overexpress a particular polypeptide can be used to obtain substantially pure polypeptides. Furthermore, polypeptides can be engineered to include amino acid sequences that allow the polypeptide to be captured on affinity matrices. For example, tags such as c-myc, hemagglutinin, polyhistidine, or Flag™ tag (Kodak) can be used to aid in the purification of the polypeptide. Such tags can be inserted anywhere within the polypeptide, including either the carboxyl or amino terminus, or a position in between. Other fusions that can be used include enzymes that aid in the detection of the polypeptide, such as alkaline phosphatase.

[0036] MANPs (e.g., variant MANPs having conservative and / or non-conservative substitutions with respect to SEQ ID NO:3), as well as fragments of SEQ ID NO:3 or variant MANPs (e.g., fragments of any of SEQ ID NOs:3-14), can be screened for biological activity using any of a number of assays. For example, the activity of a MANP can be assessed in vitro by examining the effect of the MANP on cGMP production in cultured cells (e.g., cultured cardiac fibroblasts, aortic endothelial cells, or glomerular cells). Cells can be cultured with the MANP (e.g., 10 -10 ~10 -4 The samples can be exposed to M. truncatulatus and assayed to assess the effect of the polypeptide on cGMP production. cGMP production can be detected and measured, for example, using a competitive RIA cGMP kit (Perkin-Elmer, Boston, Mass.).

[0037] The activity of MANPs can be assessed in vivo, for example, by examining the effects on factors such as plasma cGMP concentration, urinary cGMP excretion, net renal cGMP production, glomerular filtration rate, blood pressure, heart rate, hemodynamic function (e.g., cardiac output, pulmonary wedge pressure, systemic vascular resistance, etc.), and renal function (e.g., renal blood flow, urine volume, and sodium excretion rate, etc.) after administration to a mammal (e.g., human, non-human primate, rodent, dog, cat, pig, sheep, horse, or cow). In some cases, such parameters can be assessed after inducing hypertension in the mammal.

[0038] As used herein, the term "nucleic acid" encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Nucleic acids may be double-stranded or single-stranded. If single-stranded, the nucleic acid may be the sense strand or the antisense strand. Additionally, nucleic acids may be circular or linear.

[0039] The term "isolated" as used herein in relation to nucleic acids refers to a naturally occurring nucleic acid that is not immediately adjacent to both sequences (one at the 5' end and one at the 3' end) that are immediately adjacent to the naturally occurring genome of the original organism from which it is derived. For example, an isolated nucleic acid is not particularly limited and can be a recombinant DNA of any length, provided that one of the nucleic acid sequences that is normally present immediately adjacent to the recombinant DNA molecule in a naturally occurring genome is removed or absent. Thus, isolated nucleic acids include, but are not limited to, recombinant DNA that exists as a separate molecule independent of other sequences (e.g., cDNA or genomic DNA fragments generated by PCR or restriction enzyme treatment), as well as recombinant DNA integrated into vectors, autonomously replicating plasmids, viruses (e.g., retroviruses, adenoviruses, or herpes viruses), or genomic DNA of prokaryotes or eukaryotes. Additionally, isolated nucleic acids can include recombinant DNA molecules that are part of hybrid or fusion nucleic acid sequences.

[0040] The term "isolated" as used herein in relation to nucleic acids includes any non-naturally occurring nucleic acid, since non-naturally occurring nucleic acid sequences are not found in nature and do not have directly adjacent sequences in a naturally occurring genome. Non-naturally occurring nucleic acids, such as artificial nucleic acids, are considered isolated nucleic acids. Artificial nucleic acids can be made using common molecular cloning or chemical nucleic acid synthesis techniques. Isolated non-naturally occurring nucleic acids can be independent of other sequences or integrated into vectors, self-replicating plasmids, viruses (e.g., retroviruses, adenoviruses, or herpes viruses), or genomic DNA of prokaryotes or eukaryotes. Additionally, non-naturally occurring nucleic acids can include nucleic acid molecules that are part of hybrid or fusion nucleic acid sequences.

[0041] As will be apparent to one of skill in the art, a nucleic acid present among hundreds to millions of other nucleic acid molecules, for example, in a cDNA or genomic library, or a gel slice containing a genomic DNA restriction enzyme digest, is not considered an isolated nucleic acid.

[0042] In some cases, the isolated nucleic acid molecule is at least about 12 bases in length (e.g., at least about 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 100, 120, 130, 140, 150, 250, 500, 750, 1000, 1500, 2000, 3000, 4000, or 5000 bases in length) and can hybridize under hybridization conditions to a sense or antisense strand of a nucleic acid having a sequence encoding a MANP (e.g., a MANP having a sequence set forth in SEQ ID NO: 3, or a variant thereof). The hybridization conditions can be moderately or highly stringent hybridization conditions.

[0043] For purposes herein, moderately stringent hybridization conditions are defined as 25 mM KPO4 (pH 7.4), 5X SSC, 5X Denhardt's solution, 50 μg / mL denatured and sonicated salmon sperm DNA, 50% formamide, 10% dextran sulfate, 1-15 ng / mL probe (approximately 5x10 7 This refers to hybridization in a hybridization solution containing 100 cpm / μg of DNA at about 42° C., followed by washing at about 50° C. with a wash solution containing 2× SSC and 0.1% sodium dodecyl sulfate.

[0044] Highly stringent hybridization conditions consist of 25 mM KPO4 (pH 7.4), 5X SSC, 5X Denhardt's solution, 50 μg / mL denatured and sonicated salmon sperm DNA, 50% formamide, 10% dextran sulfate, 1-15 ng / mL probe (approximately 5x10 7This refers to hybridization at about 42° C. in a hybridization solution containing 0.2×SSC and 0.1% sodium dodecyl sulfate, followed by washing at about 65° C. in a wash solution containing 0.2×SSC and 0.1% sodium dodecyl sulfate.

[0045] An isolated nucleic acid molecule encoding a MANP can be produced using standard techniques, including, but not limited to, general molecular cloning and chemical nucleic acid synthesis techniques. For example, polymerase chain reaction (PCR) techniques can be used to obtain isolated nucleic acids containing nucleotide sequences encoding the natriuretic polypeptides described herein. PCR refers to a procedure or technique for enzymatically amplifying a target nucleic acid. Typically, sequence information from or beyond the end of the region of interest is used to design oligonucleotide primers that are sequentially identical to the opposite strand of the template. PCR can be used to amplify specific sequences from DNA and RNA, including sequences from total genomic DNA or total cellular RNA. Primers are typically 14-40 nucleotides in length, but can range from 10 nucleotides to hundreds of nucleotides. General PCR techniques are described, for example, in PCR Primer: A Laboratory Manual, edited by Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995. When RNA is used as the source of template, a complementary DNA (cDNA) strand can be synthesized using reverse transcriptase. Ligase chain reaction, strand displacement amplification, self-sustained sequence duplication, or nucleic acid sequence-based amplification (NASBA) can also be used to obtain isolated nucleic acids. See, e.g., Lewis (1992) Genetic Engineering News 12:1; Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878: and Weiss (1991) Science 254:1292.

[0046] An isolated nucleic acid encoding a MANP can also be chemically synthesized as a single nucleic acid molecule (e.g., using automated 3' to 5' DNA synthesis using phosphoramidite technology) or as a series of oligonucleotides. For example, one or more pairs of long oligonucleotides (e.g., more than 100 nucleotides) containing the desired sequence can be synthesized, each pair containing a short segment (e.g., about 15 nucleotides) of complementarity such that a double strand is formed when the oligonucleotide pair is annealed. The oligonucleotides are extended with DNA polymerase to yield one double-stranded nucleic acid molecule for each oligonucleotide pair, which can be ligated into a vector.

[0047] Furthermore, the isolated nucleic acid encoding MANP can be obtained by mutagenesis. For example, standard techniques such as oligonucleotide-directed mutagenesis and site-specific mutagenesis by PCR can be used to mutate the reference sequence. See Short Protocols in Molecular Biology, Chapter 8, Green Publishing Associates and John Wiley & Sons, Ausubel et al., eds., 1992. Non-limiting examples of natriuretic polypeptide variants are provided herein.

[0048] Also provided are vectors that contain the nucleic acids as described herein. A "vector" is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment can be inserted to cause replication of the inserted segment. An "expression vector" is a vector that contains one or more expression control sequences, and an "expression control sequence" is a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence.

[0049] In an expression vector, a nucleic acid (e.g., a nucleic acid encoding a natriuretic polypeptide) can be operably linked to one or more expression control sequences. As used herein, "operably linked" means that the expression control sequence is incorporated into a genetic construct so as to effectively control the expression of a coding sequence of interest. Examples of expression control sequences include promoters, enhancers, and transcription termination regions. A promoter is an expression control sequence that consists of a region of a DNA molecule that is typically within 100-500 nucleotides upstream of the transcription start point (generally near the start site of RNA polymerase II). To place a coding sequence under the control of a promoter, the translation start point of the translation reading frame of the polypeptide must be located between 1-50 bases downstream of the promoter. Enhancers provide expression specificity with respect to time, location, and level. Unlike promoters, enhancers can function at various distances from the transcription site. Enhancers can also be located downstream of the transcription start site. A coding sequence is "operably linked" and "under the control" of an expression control sequence in a cell if RNA polymerase is capable of transcribing the coding sequence into mRNA, which can then be translated into the protein that it encodes. Thus, expression vectors can be useful in the production of antibodies as well as other multivalent molecules.

[0050] Suitable expression vectors include, but are not limited to, plasmids and viral vectors derived from, for example, bacteriophage, baculovirus, tobacco mosaic virus, herpes virus, cytomegalovirus, retrovirus, vaccinia virus, adenovirus, and adeno-associated virus, etc. Numerous vectors and expression systems are commercially available from companies such as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen / Life Technologies (Carlsbad, CA).

[0051] Expression vectors can include tag sequences designed to facilitate subsequent manipulation (e.g., purification or localization) of the expressed nucleic acid sequence. Tag sequences, such as green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, c-myc, hemagglutinin, or Flag™ tag (Kodak, New Haven, CT) sequences, are usually expressed as fusions with the encoded polypeptide. Such tags can be inserted anywhere within the polypeptide, such as at the carboxyl or amino terminus.

[0052] Host cells containing the vector are also provided. The term "host cell" is intended to include prokaryotic and eukaryotic cells into which a recombinant expression vector (e.g., a vector encoding MANP) can be introduced. As used herein, "transformed" and "transfected" encompass the introduction of a nucleic acid molecule (e.g., a vector) into a cell by one of a number of techniques. Without being limited to a particular technique, many of these techniques are well established in the art. Suitable methods for transforming and transfecting host cells can be found, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual (2 ndedition), Cold Spring Harbor Laboratory, New York (1989). Nucleic acids can be introduced into cells using, for example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and virus-mediated nucleic acid transfer. Additionally, naked DNA can be delivered directly to cells in vivo, as described elsewhere (U.S. Patent Nos. 5,580,859 and 5,589,466). It is noted that while host cells can express the encoded polypeptide, cells containing the isolated nucleic acid molecules described herein need not express the polypeptide. The isolated nucleic acid molecules transformed into host cells can be integrated into the genome of the cells or maintained in an episomal state. Thus, host cells can be stably or transiently transfected with constructs containing the isolated nucleic acid molecules described herein.

[0053] Any suitable method can be used to introduce the isolated nucleic acid molecule into cells in vivo or in vitro.For example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and virus-mediated nucleic acid transfer are methods that can be used to introduce the isolated nucleic acid molecule into cells.Also, naked DNA can be directly delivered to cells in vivo, as described elsewhere (e.g., U.S. Patent Nos. 5,580,859 and 5,589,466, and their continuations).In addition, the isolated nucleic acid molecule can be introduced into cells by generating transgenic animals.

[0054] Any suitable method can be used to identify the cells that contain the isolated nucleic acid molecule that codes for MANP. Such methods include PCR and nucleic acid hybridization techniques such as Northern and Southern analysis. In some cases, immunohistochemistry and biochemistry techniques can be used to determine whether a cell contains a specific isolated nucleic acid molecule by detecting the expression of the polypeptide that the nucleic acid molecule codes for.

[0055] The isolated MANPs, nucleic acids encoding MANPs, and diuretics described herein can be used to treat mammals identified as having a disease, such as hypertension (e.g., RH). Thus, one or more diuretics and one or more MANPs, or nucleic acids encoding one or more MANPs, can be incorporated into a composition for administration to a mammal (e.g., a mammal having or at risk for hypertension, RH, and / or cardiorenal disease). Any suitable method can be used to prepare and subsequently administer the composition. Dosage typically depends on the responsiveness of the mammal to the administered agent, with the course of treatment lasting from several days to several months or more, or until an appropriate response is obtained. Those skilled in the art routinely determine optimal dosages, methods of administration, and repetitions. Optimal dosages may vary depending on the relative potency of each agent (e.g., MANPs and Fs), but generally will be determined based on the EC that is found to be effective in in vitro and / or in vivo animal models. 50The dose of one or more MANPs and one or more diuretics described herein may be administered once or more times a day, once or more times a week, once or more times a month, or even less frequently, but may be administered continuously for a period of time (e.g., hours, days, or weeks). For example, the MANP or the composition containing the MANP may be administered to a patient at a dose of at least about 0.01 ng MANP / kg body weight to about 100 mg MANP / kg body weight. In some cases, the MANP or the composition containing the MANP may be administered as an infusion (e.g., at a dose of about 1 pmol MANP / kg / min to about 500 nmol MANP / kg / min) for 1 to 30 days or longer.

[0056] One or more MANPs, or nucleic acids encoding one or more MANPs, and one or more diuretics can be admixed, encapsulated, conjugated, or otherwise associated with each other and / or with other molecules, molecular structures, or mixtures of compounds, such as liposomes, receptor or cell targeting molecules, or oral, topical, or other formulations, to aid in uptake, distribution, and / or absorption.

[0057] In some embodiments, the composition can contain MANP (or a nucleic acid encoding MANP), a diuretic, or both, in combination with a pharma- ceutically acceptable carrier. Pharmaceutically acceptable carriers include, for example, pharma- ceutically acceptable solvents, suspending agents, or any other pharmacologically inert vehicles for delivering a polypeptide and / or other compounds to a subject. Pharmaceutically acceptable carriers can be liquid or solid and can be selected in consideration of the planned method of administration to provide the desired volume, consistency, and other suitable transport and chemical properties when combined with one or more therapeutic compounds and any other components of a given pharmaceutical composition. Useful pharma-ceutically acceptable carriers include, but are not limited to, water, saline, binders (e.g., polyvinylpyrrolidone or hydroxypropylmethylcellulose), bulking agents (e.g., lactose or glucose and other sugars, gelatin, or calcium sulfate), lubricants (e.g., starch, polyethylene glycol, or sodium acetate), disintegrants (e.g., starch, or sodium starch glycolate), and wetting agents (e.g., sodium lauryl sulfate).

[0058] The MANP or nucleic acid and the diuretic can be in the same composition, but can also be in separate compositions administered at the same or different times, and administered by the same or different routes. The pharmaceutical compositions containing the MANP and diuretic described herein can be administered in a number of ways, depending on whether local or systemic treatment is desired. Administration can be, for example, oral or parenteral (e.g., subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous (iv) infusion). Administration can be rapid (e.g., by injection) or over a period of time (e.g., by slow infusion or administration of a sustained release formulation).

[0059] Compositions and formulations for parenteral, intrathecal, or intraventricular administration include sterile aqueous solutions (e.g., sterile saline), which may also contain buffers, diluents, and other suitable additives (e.g., penetration enhancers, carrier compounds, and other pharma- ceutical acceptable carriers). Compositions and formulations for oral administration include, for example, powders or granules, suspensions or solutions in water or non-aqueous solvents, capsules, sachets, or tablets. Such compositions may also incorporate thickeners, flavorings, diluents, emulsifiers, dispersing aids, or binders.

[0060] Pharmaceutical compositions include, but are not limited to, solutions, emulsions, aqueous suspensions, liposome-containing formulations, etc. These compositions can be made from various components, such as preformed liquids, self-emulsifying solids, and self-emulsifying semisolids. Emulsions are particularly useful for oral administration of therapeutic compositions, as they are easy to formulate and have benefits in terms of solubilization, absorption, and bioavailability. Liposomes can be particularly useful in terms of drug delivery, due to their specificity and the duration of action they provide.

[0061] The composition can contain any pharma- ceutically acceptable salt, ester, or salt of such an ester, or any other compound that, upon administration to a subject, can provide (directly or indirectly) a biologically active metabolite or residue thereof for the compound (e.g., MANP or diuretic). Thus, for example, the present specification provides pharma- ceutically acceptable salts of MANP and diuretic, prodrugs and pharma- ceutically acceptable salts of such prodrugs, and other bioequivalents. Prodrugs are therapeutic agents that are prepared in an inactive form and are converted to an active form (i.e., a drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and / or conditions. The term "pharma-ceutically acceptable salt" refers to physiologically and pharma- ceutically acceptable salts of MANP and diuretic useful in the methods described herein (i.e., salts that retain the desired biological activity of the parent compound without imparting undesirable toxic effects). Examples of pharma- ceutically acceptable salts include, but are not limited to, salts formed with cations (e.g., sodium, potassium, calcium, or polyamines such as spermine); acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid); salts formed with organic acids (e.g., acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid); and salts formed with elemental anions (e.g., bromine, iodine, or chlorine).

[0062] The composition can additionally contain other auxiliary components that are conventionally included in pharmaceutical compositions.Thus, the composition can also contain non-interacting pharma- ceutically active substances, such as antipruritic agents, astringents, local anesthetics or anti-inflammatory agents, or additional materials that are useful for physically preparing various dosage forms of the composition, such as dyes, flavoring agents, preservatives, antioxidants, opacifying agents, thickening agents, and stabilizers.Furthermore, the composition can also be mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, buffers, coloring agents, flavoring agents, penetration enhancers, and aromatic substances.However, when added, these substances should not unduly interfere with the biological activity of other components in the composition.

[0063] In some cases, MANPs can be formulated as sustained release formulations. For example, MANPs or diuretics can be formulated into sustained release formulations. In some cases, coatings, envelopes, or protective materials can be formulated to contain one or more MANPs described herein. Such coatings, envelopes, and protective materials can be used to coat indwelling devices such as stents, catheters, and peritoneal dialysis tubes. In some cases, polypeptides can be incorporated into polymeric substances, liposomes, microemulsions, microparticles, nanoparticles, or waxes.

[0064] The pharmaceutical preparations described herein may be conveniently in unit dosage form and can be prepared according to any suitable method, including conventional techniques known in the pharmaceutical industry. Such techniques include combining active ingredients with desired pharmaceutical carriers. Typically, the preparations can be prepared by uniformly and intimately combining active ingredients with liquid carriers or finely divided solid carriers, or both, and then shaping the product as needed. The preparations can be sterilized as needed, provided that the sterilization method does not interfere with the effectiveness of one or more molecules contained in the preparation.

[0065] In some embodiments, diuretics such as MANP and / or Fs can be formulated for subcutaneous administration by injection, depot polymer, drug patch, pump, or microparticle / nanoparticle. As a non-limiting example, PCT Publication No. WO2008 / 061355 discloses materials and methods for formulating polypeptides for delivery in hydrogel tubes. The polypeptide can be mixed with one or more additives that are pharma- ceutically acceptable and do not interact with the polypeptide in an amount suitable for use in the methods described herein. For example, the polypeptide can be combined with one or more additives, such as, but not limited to, microcrystalline cellulose, colloidal silicon dioxide, lactose, starch, sorbitol, cyclodextrin, and combinations thereof. The additives can be solid, semi-solid, or liquid materials that act as vehicles, carriers, or solvents for the polypeptide. In some embodiments, the polypeptide can be compressed, molded, or extruded with one or more additives before being inserted into the hydrogel tube. Such formulations can result in pharmaceutical compositions having desirable release characteristics, improved stability, and / or other desirable properties.

[0066] The pharmaceutical composition may include auxiliary agents or additives, such as glidants, solubilizers, surfactants, diluents, binders, disintegrants, and / or lubricants. For example, solubilizers can increase the dissolution rate of the polypeptide from the administered formulation, and can include, for example, organic acids and / or salts of organic acids (e.g., citric acid and sodium citrate). Other examples of additives useful in such formulations include synthetic, semi-synthetic, modified and natural polymers (e.g., lactose, glucose, sucrose, trehalose, sorbitol, mannitol, starch, gum arabic, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, PEG, cyclodextrin, alkoxy-modified cyclodextrin, hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, albumin, dextran, maltitol, xylitol, kaolin, and methylcellulose). The polypeptides can also be mixed with lubricating agents (e.g., talc, magnesium stearate, stearic acid or mineral oil, calcium stearate, hydrogenated vegetable oils, sodium benzoate, sodium chloride, leucine carbowax, magnesium lauryl sulfate, or glyceryl monostearate), wetting agents, emulsifying and suspending agents, or preservatives (e.g., methyl or propyl hydroxybenzoates).

[0067] Other agents that can be added to the pharmaceutical composition can alter the pH of the microenvironment involved in dissolving the MANP or diuretic and establishing a therapeutically effective plasma concentration profile. Such agents include salts of inorganic acids and magnesium hydroxide. Other agents that can be used include surfactants and other solubilizing agents.

[0068] Useful diluents include, for example, microcrystalline cellulose, lactose, sucrose, fructose, glucose, or other sugars, dicalcium phosphate, calcium sulfate, cellulose, ethyl cellulose, cellulose derivatives, kaolin, mannitol, lactitol, maltitol, xylitol, sorbitol, or other sugar alcohols, dry starch, saccharides, dextrin, maltodextrin, or other polysaccharides, inositol, or combinations thereof. In some cases, water-soluble diluents may be particularly useful.

[0069] Glidants can be used to improve the flow and compressibility of the composition components during processing. Useful glidants include, for example, colloidal silicon dioxide (also called colloidal silica, fumed silica, light silicic acid, silicic acid anhydrous, and fumed silicon dioxide).

[0070] Suitable surfactants for use in the pharmaceutical compositions described herein include, but are not limited to, sodium lauryl sulfate, polyethylene stearate, polyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxyethylene alkyl ethers, benzyl benzoate, cetrimide, cetyl alcohol, docusate sodium, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, lecithin, medium chain triglycerides, monoethanolamine, oleic acid, poloxamer, polyvinyl alcohol, and sorbitan fatty acid esters.

[0071] Suitable disintegrants include, for example, starch, sodium starch glycolate, crospovidone, croscarmellose, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, pectin, potassium methacrylate-divinylbenzene copolymer, polyvinyl alcohol, thylamide, sodium bicarbonate, sodium carbonate, starch derivatives, dextrin, beta cyclodextrin, dextrin derivatives, magnesium oxide, clay, bentonite, and combinations thereof.

[0072] In some embodiments, MANP and / or diuretic can be incorporated into hydrogel delivery system.For example, MANP can be formulated for subcutaneous administration to patient via xerogel-hydrogel system that can continuously release polypeptide over a long period of time.See, for example, U.S. Patent No. 5,226,325 and PCT Publication No. WO 2004 / 071736.

[0073] Polymerizable liquid materials useful for preparing hydrogel tubes include various polymerizable hydrophilic compounds and ethylenically unsaturated compounds. For example, see the compounds described in PCT Publication No. WO2008 / 061355. A mixture of such hydrophilic monomers is typically used in the polymerization reaction. The type and ratio of monomers are selected to obtain a polymer (e.g., a crosslinked homogeneous polymer) that, upon hydration, has the desired properties (e.g., equilibrium water content (EWC) value and / or pore size) for the intended application or use.

[0074] In some cases, the polymerization of the hydrophilic monomer mixture can result in a homogeneous hydrophilic copolymer that is more or less soluble in aqueous media. In such cases, a small amount (e.g., up to about 3%) of a copolymerizable polyethylenically unsaturated crosslinker can be included in the monomer mixture to obtain a homogeneous crosslinked copolymer that is water insoluble and water swellable. A slightly crosslinked homopolymer of hydroxyethyl methacrylate (HEMA) has an EWC value of about 38%. Crosslinked copolymers of HEMA and acrylamide exhibit EWC values ​​greater than 38 w / v%, whereas crosslinked copolymers of HEMA and N-(2-hydroxypropyl) methacrylamide (HPMA) have EWC values ​​less than 38%. Thus, depending on the useful or effective elution rate of the polypeptide, the copolymer hydrogel can be customized to elute the polypeptide at the desired rate. Typically, the copolymer contains about 15 to about 70% by weight of HEMA units and about 85 to 30% by weight of a second ethylenic monomer, thereby having an EWC value in the range of about 20 to about 75%. In some embodiments, the copolymer mixture may further contain a small amount of a polyethylenically unsaturated crosslinker, such as ethylene glycol dimethacrylate (EDMA) or trimethylolpropane trimethacrylate (TMPTMA).

[0075] In some embodiments, a pharmaceutical composition for sustained delivery of MANPs in a subject can include (a) a complex of a polypeptide (wherein the polypeptide has at least one basic functional group) and a polyanion derived from hexahydroxycyclohexane (wherein the polyanion has at least two negatively charged functional groups); and (b) a pharma- ceutically acceptable carrier comprising a biodegradable, water-insoluble polymer. Such compositions are described, for example, in PCT Publication No. WO2006 / 017852 and can be prepared, for example, in the form of a solution, suspension, dispersion, emulsion, drop, aerosol, cream, semisolid, paste, capsule, tablet, solid implant, or microparticle. The term "sustained delivery" as used herein means the continuous delivery of an agent in vivo for a period of time (e.g., days to weeks or months) after administration. Sustained sustained delivery of MANPs can be demonstrated, for example, by the therapeutic effect of the polypeptide continuing for an extended period of time (e.g., the symptoms are continuously alleviated for an extended period of time). Sustained delivery of the polypeptide can also be demonstrated by detecting the presence of the polypeptide in vivo over time. The compositions of the present invention can provide an initial low burst of delivery followed by a stable sustained release of the polypeptide in vivo over an extended period of time (e.g., days to months).

[0076] In such an embodiment, the polypeptide and the polyanion can be appropriately combined to form a physically and chemically stable complex. The complex can be in the form of a precipitate produced by combining aqueous formulations of the polypeptide and the polyanion. If necessary, one or more pharma- ceutically acceptable additives can be incorporated into the complex. Such additives can function as stabilizers for the polypeptide and / or the complex. Non-limiting examples of suitable additives include sodium bisulfate, p-aminobenzoic acid, thiourea, glycine, methionine, mannitol, sucrose, and PEG.

[0077] The stable complex between the polypeptide and the polyanion can be incorporated into a pharma- ceutically acceptable carrier, including a biodegradable water-insoluble polymer, optionally with one or more additives. The term "biodegradable water-insoluble polymer" refers to a biocompatible and / or biodegradable synthetic and natural polymer that can be used in vivo. The term also includes polymers that are insoluble or become insoluble in water or body fluids at 37°C. The polymer can be purified (e.g., to remove monomers and oligomers) using techniques known in the art. See, for example, U.S. Patent No. 4,728,721. Examples of useful polymers include, but are not limited to, polylactides, polyglycolides, poly(lactide-co-glycolides), polycaprolactones, polydioxanones, polycarbonates, polyhydroxybutyric acids, polyalkylene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyorthocarbonates, polyphosphazenes, polyhydroxyvaleric acids, polyalkylene succinates, and polyorthoesters, as well as copolymers, block copolymers, branched copolymers, terpolymers, and combinations thereof.

[0078] The biodegradable water-insoluble polymers can also include endcapped polymers, non-endcapped polymers, or mixtures of endcapped and non-endcapped polymers. An uncapped polymer has a free carboxyl end group, whereas an endcapped polymer is generally defined as having a capped carboxyl end group.

[0079] Factors to consider in determining the appropriate molecular weight for a polymer include the desired rate of degradation of the polymer, mechanical strength, and rate of dissolution of the polymer in a solvent, etc. Useful molecular weights for polymers can be, for example, from about 2,000 Daltons to about 150,000 Daltons and can have a polydispersity of 1.1 to 2.8 depending on the choice of polymer used.

[0080] Pharmaceutically acceptable carriers are carriers that have environmentally responsive properties (e.g., temperature sensitivity, pH sensitivity, electrical thermosensitivity) and can be in the form of injectable solutions or suspensions, particles, films, pellets, cylinders, discs, microcapsules, microspheres, nanospheres, microparticles, oblates, micelles, liposomes, or any other polymeric structures useful for drug delivery.

[0081] Methods for forming various pharma- ceutical acceptable polymer carriers are known in the art.See, for example, U.S. Patent Nos. 6,410,044, 5,698,213, 6,312,679, 5,410,016, 5,529,914, 5,501,863, 4,938,763, 5,278,201 and 5,278,202, and PCT Publication No. WO 93 / 16687.

[0082] Polypeptide / polyanion complexes can be dispersed in a polymer matrix to form solid implants, making compositions that can be injected or implanted into subjects. Such implants can be prepared using conventional polymer melt processing techniques, such as extrusion, compression molding, and injection molding. Such implants can be prepared in an aseptic state or by terminal sterilization by irradiation (e.g., using gamma irradiation or electron beam sterilization).

[0083] In some embodiments, compositions in the form of microspheres can be made by encapsulating the polypeptide / polyanion complex in a polymer carrier using various biocompatible and / or biodegradable polymers with properties suitable for delivery to different biological environments or to perform specific functions. The dissolution rate of the polypeptide, and thus the delivery rate, is determined by factors such as the encapsulation technique, the polymer composition, the crosslinking of the polymer, the thickness of the polymer, the solubility of the polymer, and the size and solubility of the polypeptide / polyanion complex.

[0084] To prepare such microspheres, the polypeptide / polyanion complex to be encapsulated can be suspended in a polymer solution in an organic solvent, so that the polypeptide / polyanion complex is completely coated by the polymer solution. This suspension can then be subjected to a microencapsulation technique such as spray drying, spray congealing, emulsion, or solvent evaporation emulsion. For example, the suspended complex or microparticles can be transferred with the polymer in the organic solvent into a larger volume of aqueous solution containing an emulsifier, so that the organic solvent evaporates or diffuses out of the polymer, so that the polypeptide / polyanion complex is encapsulated by the solidified polymer.

[0085] Emulsifiers useful for preparing encapsulated polypeptide / polyanion complexes include, for example, poloxamers and polyvinyl alcohol. Organic solvents useful in such methods include acetic acid, acetone, methylene chloride, ethyl acetate, chloroform, and other non-toxic solvents, depending on the properties of the polymer. Typically, a solvent is chosen that solubilizes the polymer and is ultimately non-toxic.

[0086] In some embodiments, MANPs can be formulated into a depot, which can provide a constant high exposure level and can reach high exposure levels quickly (no or short lag phase). See, for example, US Publication No. 2010 / 0266704. The depot can contain MANPs or a pharma- ceutical acceptable salt thereof (e.g., an acid addition salt with an inorganic acid, a polymeric acid, or an organic acid). The acid addition salt can exist as a monovalent or divalent salt, depending on whether one or two equivalents of acid are added.

[0087] As described in U.S. Publication No. 2010 / 0266704, the depot can contain two different linear polylactic-co-glycolic acid (PLGA) polymers with a lactide:glycolide comonomer (L:G) molar ratio of 85:15 to 65:35, at least one of which has a low intrinsic viscosity. Such formulations can provide high plasma levels of the polypeptide that are sustained over an extended period of time. Examples of suitable polymers include linear poly(D,L-lactide) and poly(D,L-lactide-co-glycolide), sold under the trade names RESOMER®, LACTEL®, and MEDISORB®, respectively, by Boehringer Ingelheim Pharma GmBH & Co. KG (Ingelheim, Germany), Absorbable Polymers International (Pelham, AL), and Alkermes, Inc. (Cambridge, MA).

[0088] High exposure depot formulations for subcutaneous administration are fast acting, or at least very fast acting, such that therapeutically effective plasma concentrations are achieved within a short period of time (e.g., 1, 2, 3, 4, 5, 6, or 7 days after subcutaneous injection), and can provide consistently high exposure levels for about a month or more.

[0089] In some embodiments, the depot described herein can contain two different PLGA polymers, which are mixed or blended in a % weight ratio of 95:5 to 50:50 (e.g., 85:15 to 50:50, 80:20 to 60:40, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50). In some embodiments, the polymer with the higher intrinsic viscosity can have a higher weight % than the polymer with the lower intrinsic viscosity. In some embodiments, the polymer with the higher intrinsic viscosity can have ester end groups. The depot can contain additional polymers, such as other linear or star-shaped PLGA polymers, or poly(D,L-lactide-co-glycolide) (PLG) or polylactic acid (PLA) polymers, provided that favorable PK properties are maintained.

[0090] The polypeptide content (loading) of the depot can be in the range of 1% to 30% (e.g., 10% to 25%, more preferably 15% to 20%). Loading is defined as the weight ratio of the polypeptide to the total mass of the PLGA formulation.

[0091] The depot composition may be manufactured aseptically or non-aseptically and terminally sterilized (e.g., using gamma irradiation), which provides a product with the highest possible assurance of sterility.

[0092] The depot composition may also contain one or more pharmaceutical additives capable of modifying the release behavior of the polypeptide. Such additives may be present in the composition in an amount of about 0.1% to about 50%. Suitable additives include, but are not limited to, polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, dextrin, PEG, surfactants such as poloxamer (also known as poly(oxyethylene-block-oxypropylene)), poly(oxyethylene) sorbitan fatty acid esters (sold under the trade name TWEEN®), sorbitan fatty acid esters, lecithin, inorganic salts such as zinc carbonate, magnesium hydroxide, magnesium carbonate, protamine, and natural or synthetic polymers with amine residues such as polylysine.

[0093] Depot composition can contain mixtures or blends of polymers that differ in composition, molecular weight, and / or polymer structure.Polymer blend is defined herein as a solid solution or suspension of two different linear polymers in one implant or microparticle.Depot mixture is defined herein as a mixture of two depot-like implants or microparticles or semi-solid formulations of different composition, each containing one or more PLGA in depot.Depot pharmaceutical composition in which two PLGAs are present as polymer blends may be particularly useful.

[0094] Depot pharmaceutical compositions can be in the form of implants, semi-solids (gels), solutions, microparticles, or suspensions that solidify in situ upon injection. The following section focuses on polymeric microparticles, but the discussion is also applicable to implants, semi-solids, and liquids.

[0095] The microparticles can have a diameter of a few submicrons to several millimeters (e.g., from about 0.01 microns to about 2 millimeters, from about 0.1 microns to about 500 microns, from about 10 to about 200 microns, from about 10 to about 130 microns, or from about 10 to about 90 microns).

[0096] In some embodiments, the microparticles can be mixed with or coated with an anti-agglomerating agent. Suitable anti-agglomerating agents include, for example, mannitol, glucose, dextrose, sucrose, sodium chloride, and water-soluble polymers such as polyvinyl alcohol, polyvinylpyrrolidone, and PEG.

[0097] Microparticles can be produced using processes known in the art, such as coacervation or phase separation, spray drying, or water-in-oil (W / O), water-in-oil-in-water (W / O / W), or solid-in-oil-in-water (S / O / W) emulsion / suspension techniques followed by solvent extraction or solvent evaporation. Emulsion / suspension techniques are particularly useful and can include the following steps: (i) preparing an internal organic phase, comprising: (a) dissolving one or more polymers in a suitable organic solvent (e.g., ethyl acetate, acetone, THF, acetonitrile, or halogenated hydrocarbons such as methylene chloride, chloroform, or hexafluoroisopropanol) or solvent mixture and, if necessary, dissolving / dispersing suitable additives; (b) dissolving / suspending / emulsifying the polypeptide in the polymer solution obtained in step (a); the steps including: (ii) preparing an outer aqueous phase containing one or more stabilizing agents (e.g., poly(vinyl alcohol), hydroxyethyl cellulose, hydroxypropyl cellulose, poly(vinylpyrrolidone), or gelatin), and optionally buffer salts; (iii) mixing the internal organic phase with the external aqueous phase to form an emulsion; and (iv) hardening the microparticles by solvent evaporation or solvent extraction, washing the microparticles (e.g., with water), recovering the microparticles, drying the microparticles (e.g., by freeze-drying or drying under vacuum), and sieving the microparticles (e.g., through a 140 μm sieve).

[0098] The dried microparticle composition can be terminally sterilized by gamma irradiation, either in bulk or after dispensing into final containers, hi some embodiments, the bulk sterilized microparticles can be resuspended in a suitable solvent and dispensed into a suitable device, such as a dual chamber syringe, and then lyophilized.

[0099] In some embodiments, the microparticle depot composition can include a solvent to facilitate reconstitution.Furthermore, prior to administration, the microparticles can be suspended in a suitable injectable solvent (e.g., an aqueous solvent containing one or more pharmaceutical excipients, such as mannitol, sodium chloride, glucose, dextrose, sucrose, or glycerin, and / or one or more non-ionic surfactants, such as poloxamer, poly(oxyethylene)sorbitan fatty acid ester, sodium carboxymethylcellulose, sorbitol, poly(vinylpyrrolidone), or aluminum monostearate).

[0100] Also provided herein is a method for treating a mammal having a cardiovascular disease (e.g., hypertension, resistant hypertension, or myocardial infarction). The method can include administering (e.g., orally, parenterally, or a combination of oral and parenteral methods) a MANP and a diuretic as described herein. The treatment can favorably affect or alleviate one or more symptoms associated with the disease, or one or more underlying causes of the disease. For example, the treatment can reduce the blood pressure of the mammal.

[0101] Prior to administering to the mammal a MANP or nucleic acid and a diuretic, or one or more compositions containing a MANP and a diuretic, the mammal can be evaluated to determine whether there is a need to treat a cardiovascular disease, such as hypertension (e.g., RH). After identifying the mammal as in need of such treatment, the mammal can be treated with the compositions described herein. For example, a composition containing a MANP can be administered to the mammal in any amount, at any time, and for any period of time effective to achieve the desired result (e.g., lowering the mammal's blood pressure or preventing or delaying a further increase in the mammal's blood pressure).

[0102] In some embodiments, a composition containing MANP can be administered parenterally (e.g., by injection, such as subcutaneous injection) or by oral ingestion at a dose of about 0.01 ng polypeptide / kg body weight to about 100 mg polypeptide / kg body weight (e.g., about 10 ng polypeptide / kg body weight to about 50 mg polypeptide / kg body weight, about 20 ng polypeptide / kg body weight to about 10 mg polypeptide / kg body weight, about 0.1 ng polypeptide / kg body weight to about 20 ng polypeptide / kg body weight, about 3 ng polypeptide / kg body weight to about 10 ng polypeptide / kg body weight, about 10 ng polypeptide / kg body weight to about 100 mg polypeptide / kg body weight). about 50 ng polypeptide / kg body weight, about 50 ng polypeptide / kg body weight to about 100 μg polypeptide / kg body weight, about 1 μg polypeptide / kg body weight to about 10 μg polypeptide / kg body weight, about 1 μg polypeptide / kg body weight to about 5 μg polypeptide / kg body weight, about 3 μg polypeptide / kg body weight to about 7 μg polypeptide / kg body weight, about 5 μg polypeptide / kg body weight to about 10 μg polypeptide / kg body weight, about 10 μg polypeptide / kg body weight to about 20 μg polypeptide / kg body weight, or about 20 μg polypeptide / kg body weight to about 100 μg polypeptide / kg body weight), although beneficial results may be obtained with other dosages. In some cases, MANP can be administered by infusion at a dose of, for example, about 1 pmol / kg / min to about 500 nmol / kg / min (e.g., about 1-10 pmol / kg / min, about 10-100 pmol / kg / min, about 100-300 pmol / kg / min, about 250-500 pmol / kg / min, about 500 pmol / kg / min to about 1 nmol / kg / min, about 1-10 nmol / kg / min, about 10-100 nmol / kg / min, about 100-300 nmol / kg / min, or about 250-500 nmol / kg / min).

[0103] The diuretic can be administered at a dose of at least about 1 μg / kg body weight to about 500 mg / kg body weight (e.g., about 1-10 μg / kg body weight, about 10-50 μg / kg body weight, about 50-100 μg / kg body weight, about 100-500 μg / kg body weight, about 500 μg / kg body weight to about 1 mg / kg body weight, about 1-5 mg / kg body weight, about 5-10 mg / kg body weight, about 10-50 mg / kg body weight, about 50-100 mg / kg body weight, or about 100-500 mg / kg body weight), although other doses may also provide beneficial results. Of note, given the potentiating effect of MANP, the dose of the diuretic can be reduced over time. Thus, the diuretic may be administered at a dose of about 1-5 mg / kg initially, but the dose can be tapered over time.

[0104] The MANP and diuretic can be administered once (e.g., by implantation of a depot composition, or injection), or more than once (e.g., by repeated injections, or oral administration). When administered multiple times, the frequency of administration can range from once or more than once a day (e.g., once, twice, three times, four times, or five times or more per day) to about once every other month (e.g., 3-5 times a week, about once a week, about twice a month, about once a month, or about once every other month). Furthermore, the frequency of administration can remain constant or can vary during the treatment period. Various factors can affect the actual administration frequency used for a particular application. For example, the effective amount, the duration of treatment, the route of administration, and the severity of the disease may require an increase or decrease in the frequency of administration.

[0105] In some embodiments, a MANP natriuretic polypeptide, or a MANP-containing composition, can be administered by a first route (e.g., intravenously) for a first period of time and then via another route (e.g., subcutaneously) for a second period of time. For example, a MANP-containing composition can be administered intravenously to a mammal (e.g., a human) at a dose of about 1 pmol / kg / min to about 500 nmol / kg / min for 1 hour to 7 days (e.g., 1 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 ​​to 36 hours, 3 to 4 days, 4 to 5 days, 5 to 6 days, or 6 to 7 days), and then subcutaneously to the mammal at a dose of about 0.01 ng / kg to about 100 mg / kg, once to three times a day, for 5 to 30 days or more (e.g., 5 to 7 days, 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 30 days, or 31 days or more).

[0106] An effective amount of a MANP (or a nucleic acid encoding a MANP) and a diuretic administered to a mammal is an amount sufficient to change a selected parameter (e.g., blood pressure) by at least 10%. For example, in some embodiments, an "effective amount" of a MANP and a diuretic is an amount sufficient to increase natriuresis and / or diuresis (or to increase natriuresis and / or diuresis, such as plasma cGMP levels, urinary cGMP excretion, net renal cGMP production, urine flow, urinary sodium excretion, urinary potassium excretion, hematocrit, plasma BNP immunoreactivity, renal blood flow, plasma ANP immunoreactivity, renal vascular resistance, proximal and distal fractional reabsorption of sodium, mean arterial pressure, pulmonary capillary wedge pressure, right atrial pressure, pulmonary artery pressure, plasma renin activity, plasma angiotensin II concentration, plasma aldosterone concentration, renal perfusion pressure, and systemic vascular resistance). is an amount sufficient to increase or decrease the diuretic properties) by at least 10% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) compared to the level of the same parameter before treatment or compared to the level of the parameter in a control untreated mammal. Thus, in some cases, an effective amount of a MANP and a diuretic is an amount that reduces the blood pressure of a mammal identified as having hypertension (e.g., RH) by at least 10% (e.g., at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, or at least 50%) compared to the blood pressure of the mammal before administration of the MANP and the diuretic, in other words, without administration of the MANP and the diuretic, or compared to the "normal" blood pressure of a control, untreated mammal.An effective amount of a MANP can also be an amount sufficient to enhance the effect of a diuretic, such that the beneficial effect of the diuretic (e.g., blood pressure reduction) is increased (e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%) over the effect observed when the same amount of the diuretic is administered without the MANP. An effective amount of a MANP can also reduce the adverse effect of the diuretic (e.g., renin-angiotensin-aldosterone activation) by at least about 5% (e.g., at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%) compared to the adverse effect observed when the diuretic is administered without the MANP.

[0107] In some embodiments, the amount and frequency of administration of MANP and diuretic to a mammal can be titrated, for example, to identify the most effective dose for treating hypertension while minimizing side effects. If a mammal does not respond to a particular amount, the amount can be increased, for example, 2-fold, 3-fold, 5-fold, or 10-fold. After receiving this higher concentration, the mammal can be monitored for both responsiveness to treatment and toxic symptoms, and adjustments in dosage and / or frequency of administration can be made accordingly. The effective amount can remain constant, but can be adjusted as a sliding scale, i.e., variable dose, depending on the mammal's response to treatment.

[0108] The frequency of administration can be any frequency that alleviates symptoms of, for example, cardiovascular or cardiorenal disease in a mammal without causing significant toxicity to the mammal. For example, the frequency of administration can be from about 4 times a day to about once every other month, or from about once a day to about once a month, or from about once every other day to about once a week. Furthermore, the frequency of administration can remain constant during the treatment period, but can also be variable. As with the effective amount, various factors can affect the actual frequency of administration used for a particular application. For example, the effective amount, the duration of treatment, the route of administration, and the severity of the renal disease may require an increase or decrease in the frequency of administration.

[0109] The effective administration period can be any period that alleviates the symptoms of hypertension or cardiorenal disease in a mammal without causing significant toxicity to the mammal. The effective period can be a variety of periods, from one day to several days, weeks, months, or years. In general, the effective period can range from several days to several months. For example, the effective period can range from about 1-2 weeks to about 36 months or longer. In some cases, treatment may continue throughout the life of an individual mammal. Several factors can affect the actual effective period used in a particular treatment regimen. For example, the effective period can vary depending on the frequency of administration, the dosage, the route of administration, and the severity of the condition.

[0110] After administering the MANP and diuretic described herein to a mammal, the mammal can be monitored to determine whether the disease has improved. For example, the mammal can be evaluated after treatment to determine whether one or more symptoms of the mammal's disease have been alleviated (e.g., whether the mammal's blood pressure has decreased). If the mammal does not respond to a particular dose of the MANP and diuretic, the amount of one or both can be increased, for example, two-fold, three-fold, five-fold, or ten-fold. After receiving this high concentration, the mammal can be monitored for both responsiveness to the treatment and toxic symptoms, and adjusted appropriately depending on the situation. The effective amount can remain constant, but can be adjusted as a sliding scale, i.e., variable dose, depending on the mammal's response to the treatment.

[0111] In some cases, the methods described herein can include administering to a mammal one or more compositions in which the diuretic and the MANP are all active ingredients. In such cases, for example, administration can consist of administering a composition in which the MANP and the diuretic are all active ingredients, but administration can also consist of administering a first composition in which the MANP is all active ingredients and a second composition in which the diuretic is all active ingredients.

[0112] In some cases, the methods described herein can include administering to a mammal one or more compositions in which the active ingredients are either a diuretic, a MANP, and an ACE inhibitor, an ARB, or a CCB. In such cases, for example, administration can consist of administering a composition in which the active ingredients are a MANP, a diuretic, and an ACE inhibitor; or a MANP, a diuretic, and an ARB; or a MANP, a diuretic, and a CCB, but can also consist of administering a first composition in which the active ingredients are a MANP, a second composition in which the active ingredients are a diuretic, and a third composition in which the active ingredients are an ACE inhibitor, an ARB, or a CCB. It is noted that in some cases, two of the three active ingredients (e.g., a MANP and a diuretic; a MANP and an ACE inhibitor, an ARB, or a CCB; or a diuretic and an ACE inhibitor, an ARB, or a CCB) can be administered in one composition and the third active ingredient can be administered in another composition.

[0113] In some cases, the methods described herein can include administering to a mammal one or more compositions in which all active ingredients are a diuretic, a MANP, an ACE inhibitor or ARB, and a CCB. In such cases, for example, administration can consist of administering a composition in which all active ingredients are a MANP, a diuretic, an ACE inhibitor or ARB, and a CCB, but administration can also consist of administering a first composition in which all active ingredients are a MANP, a second composition in which all active ingredients are a diuretic, a third composition in which all active ingredients are an ACE inhibitor or ARB, and a fourth composition in which all active ingredients are a CCB. It is noted that in some cases, two of the active ingredients (e.g., a MANP and a diuretic, a MANP and an ACE inhibitor or ARB, a MANP and a CCB, a diuretic and an ACE inhibitor or ARB, a diuretic and a CCB, or an ACE inhibitor or ARB and a CCB) can be administered in one composition and the other two active ingredients can be administered in another composition. Additionally, in some cases, three of the active ingredients (e.g., a MANP, a diuretic, and an ACE inhibitor or ARB; a MANP, a diuretic, and a CCB; a MANP, an ACE inhibitor or ARB, and a CCB; or a diuretic, an ACE inhibitor or ARB, and a CCB) can be administered in one composition and the remaining active ingredients can be administered in another composition.

[0114] In some cases, the methods described herein can include identifying a mammal as having hypertension (e.g., RH) and then administering a MANP and a diuretic (e.g., Fs) to the mammal. The ability to identify a mammal as having hypertension or RH allows for the mammal to be properly identified and treated with a combination of a MANP and a diuretic in an effective and reliable manner. For example, the RH treatment methods described herein (e.g., a combination of a MANP and Fs) can be used to treat hypertensive patients identified as having RH.

[0115] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. EXAMPLES

[0116] [Example 1] Effects of MANP and Fs in rats A study was conducted to investigate the individual and combined effects of MANP (SEQ ID NO:3) and Fs on BP and aldosterone stimulation in spontaneously hypertensive rats (SHRs), the best-studied and widely used genetic model of human essential hypertension (Lerman et al. (2019) Hypertension 73(6):e87-e120). SHRs (n=32) were randomly divided into 10 groups: Group 1 - treated with vehicle saline (Veh); Group 2 - treated with 1 mg / kg Fs alone (Fs1); Group 3 - treated with 5 mg / kg Fs alone (Fs5); Group 4 - treated with 10 mg / kg Fs alone (Fs10); Group 5 - treated with 100 pmol / kg / min MANP alone (MANP100); Group 6 - treated with 300 pmol / kg / min MANP alone (MANP300); Group 7 - treated with 600 pmol / kg / min MANP alone (MANP600); Group 8 - processed with Fs5+MANP300; Group 9 - treated with Fs10+MANP300; and Group 10 - Processed with Fs10+MANP600. Fs was given as a single bolus dose, followed by MANP infusion over 60 min in groups 8, 9, and 10.

[0117] Mean arterial pressure (MAP, mmHg) was 0.01 mmHg at Fs1 (Δ=-40±9*), 0.01 mmHg at Fs5 (Δ=-55±8*), and 0.01 mmHg at Fs6 (Δ=-60±10*). * ), Fs10(Δ=-63±11 * ), MAN P300 (Δ = -70 ± 19* ), and MANP600 (Δ=-93±20 *&# ) alone decreased the expression level; Fs5+MANP300 (Δ=-90±15 *&# ), Fs10+MANP300(Δ=-93±6 *&# ), and Fs10+MANP600(Δ=-95±9 *&# ) combination group showed a greater effect (Fig. 2A-2C). The decrease in BP in the Fs, MANP, and Fs+MANP groups was associated with an increase in sodium excretion and urinary flow (*p<0.05), but no significant difference in sodium excretion or diuresis was observed between the Fs and Fs+MANP groups. Plasma cGMP significantly increased in the MANP and MANP+Fs groups, but did not change with Fs alone (Fig. 3A-3C). Plasma aldosterone tended to increase with low and high doses of Fs, and the increase was significantly suppressed in the Fs+MANP group (p<0.05) (Fig. 4). In particular, in the MANP+Fs group, the greater the decrease in BP, the greater the increase in cGMP (Fig. 5).

[0118] Thus, MANP+Fs showed a stronger antihypertensive effect than Fs alone and also suppressed the activation of aldosterone by Fs. Although both Fs and MANP cause diuresis and natriuresis, MANP may also be involved in vascular relaxation, which may explain the stronger antihypertensive effect of Fs+MANP. Therefore, these studies suggested that MANP is an effective additional drug to enhance the antihypertensive effect of Fs in the treatment of RH.

[0119] [Example 2] Effects of MANP and Fs in HEK293 cells and rats We further expanded our investigation of MANP to further investigate its dose-dependent acute cardiorenal and neurohumoral effects in SHRs, confirm the direct cGMP activation effect of MANP in HEK293 cells overexpressing pGC-A, and investigate MANP-mediated cGMP activation in primary human vascular cells, which are important organ injury targets in hypertension, including human aortic smooth muscle cells and human aortic endothelial cells, both of which naturally express pGC-A.

[0120] method Cell Culture: HEK293 cells were transfected with pGC-A (cDNA clone from Origene, Rockville, MD) using Lipofectamine (Invitrogen, Grand Island, NY). Transfected cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U / mL penicillin, 100 U / mL streptomycin, and 250 μg / mL G418 (Geneticin) antibiotic. HAECs (Lonza, Walkersville, MD) were cultured in EBM-2 medium (Lonza) containing EGM-2 growth factors and supplements (Lonza) and 10% FBS (Gibco). HASMCs (ScienCell, San Diego, CA) were cultured in smooth muscle cell medium (SMCM) (ScienCell) containing SMC growth supplement (SMCGS), penicillin / streptomycin (ScienCell), and FBS (ScienCell).

[0121] Intracellular cGMP: Cells were treated when 80% to 90% confluent. Briefly, cells were incubated in a buffer containing 20 mmol / L N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], 0.1% bovine serum albumin, and 0.5 mmol / L 3-isobutyl-1-methylxanthine (Sigma, St. Louis, MO). Treated cells were either untreated (control) or treated with MANP (SEQ ID NO: 3; 10-8 M, 10 -7 M, or 10 -6 M) treatment for 10 min. Experiments were performed in triplicate for each concentration of MANP or control, after which cell lysates were harvested. Samples were assayed using a Direct cGMP ELISA kit (Enzo Life Sciences, Farmingdale, NY) according to the manufacturer's protocol. Total protein concentration in samples was quantified using a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). Results are expressed as picomoles of cGMP per milligram of total protein.

[0122] Acute study protocol in SHR: The cardiorenal and neurohumoral effects of MANP, Fs, or their combination were investigated in male SHR (n=6 per group), a genetic model of hypertension. Rats were anesthetized by inhalation of 2.5% isoflurane in an induction chamber. During this brief anesthetized state, rats were maintained anesthetized with Inactin 100 mg / kg IP. An oxygen mask was used until the end of the experiment. The carotid artery was cannulated for arterial pressure measurement and the right jugular vein was cannulated for fluid infusion. Pressures were digitally recorded and analyzed (Sonometrics, London, Ontario, Canada). For urine collection, a cannula was inserted through a small incision in the lower abdominal wall.

[0123] Immediately after preparation, a 30-min equilibration period was initiated by intravenous infusion of inulin. A 15-min baseline clearance period was performed consisting of hemodynamic measurements and arterial blood sampling. After baseline measurements, rats were randomized into 10 groups. Group 1 - processed with MANP100; Group 2 - processed with MANP300; Group 3 - processed by MANP600; Group 4 - treated with Fs1; Group 5 - treated with Fs5; Group 6 - treated with Fs10; Group 7 - processed with MANP300+Fs5; Group 8 - processed with MANP300+Fs10; Group 9 - processed with MANP600+Fs10; and Group 10 - treated with inulin, saline, or inulin and saline. Groups 1-3 received a continuous infusion of MANP for a total of 60 min, followed by a 15 min lead-in of MANP infusion. Animals in groups 4-6 received a single intravenous (IV) bolus of Fs. MANP+Fs groups 7-9 received a single IV bolus of Fs, followed by a 15 min lead-in infusion of MANP, followed by a continuous infusion of the same amount of MANP for 60 min. Control animals (group 10) received a continuous infusion of inulin as a MANP control, a single IV bolus of 0.9% saline as an Fs control, and a combination of a single IV bolus of 0.9% saline and a continuous infusion of inulin as a MANP+Fs treatment control.

[0124] Neurohormonal and electrolyte analyses: Plasma ANP was measured by radioimmunoassay (Phoenix Pharmaceuticals) to assess MANP, as ANP radioimmunoassay (RIA) adequately detects MANP (Burnett et al. (1986) Science 231(4742):1145-1147). Plasma and urinary cGMP (Enzo Life Sciences) and aldosterone (DRG International, Springfield, NJ) were measured by ELISA. Inulin concentrations were measured using the anthrone method as described elsewhere (Fuhr et al. (1955) Klin. Wochenschr 33:729-730). GFR was calculated by inulin clearance. Electrolytes were measured by flame photometry (IL943, Instrumentation Laboratory, UK). All measurements were performed according to the manufacturer's instructions.

[0125] Statistical analysis: Values ​​are expressed as mean ± standard error of the mean (SEM). Comparisons of independent groups were performed with Student's t test. For comparisons within groups, one-way analysis of variance (ANOVA) test followed by Dunnett's post-hoc test was used. For comparisons between groups, two-way ANOVA test was used followed by Bonferroni's post-hoc test (Statistica 8.0). Statistical significance was defined as a p-value <0.05.

[0126] result In vitro cGMP activation in HEK293 cells overexpressing human pGC-A, as well as primary human aortic endothelial cells and human aortic smooth muscle cells: Figure 6A shows the results of in vitro measurement of cGMP production after MANP treatment of HEK293 cells transfected with human pGC-A receptor. cGMP levels increased with increasing MANP concentrations. MANP significantly increased cGMP levels compared to the untreated control group. Increasing doses of MANP also significantly increased cGMP levels in HAECs and HASMCs (Figures 6B and 6C). As with HEK 293 cells, no significant effect was observed without treatment.

[0127] In Vivo Study - Systemic Hemodynamics: Arterial blood pressure (BP) at baseline in SHRs from MANP, Fs, MANP+Fs, and control groups is shown in Table 2. The effects on blood pressure are shown in Figures 7A-7C and 8. MANP300 and MANP600 significantly reduced BP compared to the control group (Figure 7A). At 60 min, the greatest reduction in BP was seen in the high dose (MANP600) group (Figure 8). Fs at all three doses significantly reduced BP compared to the control (Figures 7B and 8). However, MANP600 alone had a significantly greater antihypertensive effect than Fs1 or Fs5 alone (Figure 8). In the combination therapy groups, the addition of MANP300 to Fs5 or Fs10, and the addition of MANP600 to Fs10, significantly reduced BP compared to Fs alone (monotherapy) (p<0.05 for MANP300+Fs5 vs. Fs5 alone, MANP300+Fs10 vs. Fs10 alone, and MANP600+Fs10 vs. Fs10 alone) (Figures 7C and 8). Thus, the combination therapy of MANP+Fs significantly enhanced the antihypertensive effect of Fs.

[0128] In Vivo Study - Neurohumoral Analysis: Data on plasma cGMP levels at baseline in the MANP, Fs, MANP+Fs, and control groups are summarized in Table 2. Plasma cGMP was measured at three time points (baseline, 30 min, 60 min) and increased dose-dependently after treatment with MANP300 and MANP600 compared to the control group (Figure 9A). In contrast, Fs did not change plasma cGMP (Figure 9B), but plasma cGMP was significantly increased in the MANP+Fs group (Figure 9C).

[0129] [Table 2]

[0130] Urinary cGMP excretion was significantly increased in a dose-dependent manner after administration of MANP300 and MANP600, and was also significantly increased after administration of MANP300+Fs5, MANP300+Fs10, and MANP600+Fs10 compared to the control (Figure 10). No significant increase was observed in the Fs group, and there was no difference from the vehicle (control) group (Figure 10).

[0131] The evaluation of aldosterone is shown in Figure 11. MANP reduced aldosterone at doses of 100 pmol / kg / min and 300 pmol / kg / min, but not at 600 pmol / kg / min. The levels of aldosterone were significantly higher in the Fs5 and Fs10 groups compared with the control, MANP100, and MANP300 groups. In the combined groups, aldosterone was significantly reduced in the MANP300+Fs5 group compared with Fs5 alone, and in the MANP300+Fs10 and MANP600+Fs10 groups compared with Fs10 alone. Thus, treatment with MANP+Fs could suppress the activation of aldosterone by Fs.

[0132] Injection of MANP alone or in combination with Fs significantly increased plasma ANP immunoreactivity, an index of MANP immunoreactivity (Table 3). Among the neurohumoral factors, plasma ANP concentration was significantly correlated with plasma cGMP (r=0.75, p<0.001) (Fig. 12). Among the hemodynamic parameters, plasma cGMP concentration was significantly correlated with BP (r=-0.65, p<0.001) (Fig. 13).

[0133] In Vivo Study - Renal Function: Effects on GFR, urinary sodium excretion (UNaV) and water excretion (UV) are plotted in Figures 14A-14C. GFR was significantly lower in the Fs group compared to the untreated control group, whereas GFR was increased in the MANP300+Fs10 and MANP600+Fs10 groups compared to the Fs group (Figure 14A). Both urinary sodium excretion (Figure 14B) and water excretion (Figure 14C) were significantly increased after administration of MANP alone and in combination with Fs.

[0134] [Table 3]

[0135] Other embodiments Although the present invention has been described in conjunction with its detailed description, it is to be understood that the foregoing description is intended to be illustrative, and not limiting, of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

[0136] SEQUENCE LISTING <110> Mayo Foundation for Medical Education and Research <120> COMBINATION TREATMENT FOR RESISTANT HYPERTENSION <130> PA24-398 <140> JP 2024-111406 <141> 2019-11-08 <150> US 62 / 758,009 <151> 2018-11-09 <160> 14 <170> PatentIn version 3.5 <210> 1 <211> 28 <212> PRT <213> Homo sapiens <400> 1 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 <210> 2 <211> 12 <212> PRT <213> Homo sapiens <400> 2 Arg Ile Thr Ala Arg Glu Asp Lys Gln Gly Trp Ala 1 5 10 <210> 3 <211> 40 <212> PRT <213> Homo sapiens <400> 3 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Trp Ala 35 40 <210> 4 <211> 123 <212> DNA <213> Homo sapiens <400> 4 agcctgcgga gatccagctg cttcgggggc aggatggaca ggattggagc ccagagcgga 60 ctgggctgta acagcttccg gtaccggata acagccaggg aggacaagca gggctgggcc 120 tag 123 <210> 5 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 5 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Ala Arg 20 25 30 Glu Asp Lys Gln Gly Trp Ala 35 <210> 6 <211> 40 <212> PRT <213> Artificial <220> <223> synthetic <400> 6 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Tyr Ala 35 40 <210> 7 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 7 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Ser Gln Gly Trp Ala 35 40 <210> 8 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 8 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln 35 <210> 9 <211> 44 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 9 Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met 1 5 10 15 Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 20 25 30 Arg Ile Thr Ala Arg Glu Asp Lys Gln Gly Trp Ala 35 40 <210> 10 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 10 Ser Leu Lys Lys Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Trp Ala 35 40 <210> 11 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> synthetic <220> <221> MISC_FEATURE <222> (6)..(6) <223> Ser is D-isoform <400> 11 Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Trp Ala 35 40 <210> 12 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> synthetic <220> <221> MISC_FEATURE <222> (4)..(4) <223> Arg is D-isoform <400> 12 Ser Leu Arg Arg Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala 1 5 10 15 Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala Arg 20 25 30 Glu Asp Lys Gln Gly Trp Ala 35 <210> 13 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 13 Thr Leu Arg Arg Thr Thr Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Trp Ala 35 40 <210> 14 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> synthetic <400> 14 Ser Trp Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Arg Ile Thr Ala 20 25 30 Arg Glu Asp Lys Gln Gly Trp Ala 35 40

Claims

1. 1. A method for treating a mammal, comprising: administering to said mammal an M atrial natriuretic peptide (MANP); and administering a diuretic to said mammal. The method comprising:

2. The method of claim 1, wherein the mammal is identified as having hypertension.

3. 3. The method of claim 2, wherein the hypertension is resistant hypertension (RH).

4. The method of any one of claims 1 to 3, wherein the MANP has the amino acid sequence set forth in SEQ ID NO:

3.

5. The method according to any one of claims 1 to 3, wherein the MANP has an amino acid sequence as set forth in any one of SEQ ID NOs: 5 to 14.

6. The method according to any one of claims 1 to 5, wherein the diuretic is furosemide.

7. The method according to any one of claims 1 to 6, wherein the mammal is a human.

8. The method of any one of claims 1 to 7, wherein the MANPs are administered intravenously.

9. The method of claim 8, wherein the MANP is administered at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min.

10. The method of any one of claims 1 to 7, wherein the MANPs are administered subcutaneously.

11. The method of claim 10, wherein the MANPs are administered at a dose of about 0.1 ng / kg to about 10 mg / kg.

12. The method of any one of claims 1 to 7, wherein the MANPs are administered intravenously and then subcutaneously.

13. 13. The method of claim 12, wherein the MANP is administered intravenously at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min, followed by subcutaneous administration at a dose of about 0.1 ng / kg to about 100 mg / kg.

14. 14. The method of any one of claims 1 to 13, wherein the diuretic is administered orally.

15. 14. The method of any one of claims 1 to 13, wherein the diuretic is administered intravenously.

16. The method of any one of claims 1 to 13, wherein the diuretic is administered subcutaneously.

17. The method according to any one of claims 1 to 16, wherein said MANP and said diuretic are administered simultaneously in the same composition.

18. 18. The method of claim 17, wherein the MANP and the diuretic are administered subcutaneously.

19. The method according to any one of claims 1 to 18, wherein said method comprises administering to a mammal a MANP and a diuretic.

20. A method for enhancing one or more beneficial effects and reducing one or more adverse effects of a diuretic in a mammal, the method comprising administering to the mammal a diuretic and a MANP.

21. 21. The method of claim 20, wherein the mammal is identified as having hypertension.

22. 22. The method of claim 21, wherein the hypertension is RH.

23. The method of any one of claims 20 to 22, wherein the MANP has the amino acid sequence set forth in SEQ ID NO:

3.

24. The method of any one of claims 20 to 22, wherein the MANP has an amino acid sequence as set forth in any one of SEQ ID NOs: 5 to 14.

25. 25. The method of any one of claims 20 to 24, wherein the diuretic is furosemide.

26. The method of any one of claims 20 to 25, wherein the mammal is a human.

27. 27. The method of any one of claims 20 to 26, wherein the MANP and the diuretic are administered intravenously.

28. 28. The method of claim 27, wherein the MANP is administered at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min.

29. The method of any one of claims 20 to 26, wherein the MANP and the diuretic are administered subcutaneously.

30. 30. The method of claim 29, wherein the MANPs are administered at a dose of about 1 μg / kg to about 10 μg / kg.

31. 27. The method of any one of claims 20 to 26, wherein the MANP and the diuretic are administered intravenously and then subcutaneously.

32. 32. The method of claim 31, wherein the MANP is administered intravenously at a dose of about 10 pmol / kg / min to about 100 nmol / kg / min, followed by subcutaneous administration at a dose of about 1 μg / kg to about 10 μg / kg.

33. 33. The method of any one of claims 20 to 32, wherein the one or more beneficial effects comprises lowering blood pressure in a mammal and the one or more adverse effects comprises aldosterone activation.

34. 34. The method according to any one of claims 20 to 33, wherein said method comprises administering a composition, wherein the diuretic and the MANP are all active ingredients in the composition.

Citation Information

Patent Citations

  • Adjuvant therapy to standard of care (SOC) diuretic treatment

    US20170020899A1

  • MANP analogues

    WO2018089601A1

Cited By

  • Combination therapy for resistant hypertension

    JP7932841B2